Loading
PF-07248144 is an experimental small-molecule drug from Pfizer in phase 3 trials for HR-positive / HER2-negative breast cancer, prostate cancer and non-small-cell lung cancer, with its target not yet stated publicly.
PF-07248144 is a small-molecule drug developed by Pfizer. The sponsor describes its target as KAT6 (lysine acetyltransferase, e.g. KAT6A), which OnCo does not yet have a target page for. The sponsor states: PF-07248144 is a KAT6 inhibitor being studied as a single agent and in combination with fulvestrant, letrozole plus palbociclib, PF-07220060 (a CDK4 inhibitor) plus fulvestrant, or vepdegestrant, in HR-positive/HER2-negative breast cancer and other solid tumours. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07062965 (A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment), in HR-positive / HER2-negative breast cancer, prostate cancer and non-small-cell lung cancer. The largest, NCT07062965, plans to enrol 400 participants with primary completion expected 2027-07-22. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
PF-07248144 is a KAT6 inhibitor being studied as a single agent and in combination with fulvestrant, letrozole plus palbociclib, PF-07220060 (a CDK4 inhibitor) plus fulvestrant, or vepdegestrant, in HR-positive/HER2-negative breast cancer and other solid tumours.
1.PF-07248144 slips into a pocket on its target.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"PF-07248144" OR ABSTRACT:"PF-07248144") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PF-07248144, not a curated reading list.
Shares HR-positive / HER2-negative breast cancer, Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
Shares Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag pipeline.